NCT03815643 2026-03-31Avelumab Program Rollover StudyEMD SeronoPhase 3 Active not recruiting205 enrolled
NCT05267626 2026-03-31Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerAulos Bioscience, Inc.Phase 1/2 Recruiting159 enrolled
NCT04902040 2026-03-18Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesM.D. Anderson Cancer CenterPhase 1/2 Terminated19 enrolled 11 charts
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT04260802 2026-01-12A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersOcellaris Pharma, Inc.Phase 1/2 Terminated73 enrolled
NCT04551885 2023-09-21FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated12 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT01772004 2021-12-20Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)EMD SeronoPhase 1 Completed1,756 enrolled 59 charts